Cyclooxygenase-2 Inhibition Prevents Colorectal Cancer: From the Bench to the Bed SideSamoha S. · Arber N.
Integrated Cancer Prevention Center, Tel Aviv Medical Center, Tel Aviv University, Tel Aviv, Israel
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Cancer is predicted to become the leading cause of death – surpassing heart disease – by the end of this decade. Colorectal cancer is a major health concern, with more than 1,000,000 new cases and 500,000 deaths expected worldwide per year. There is much evidence to suggest a link between the consumption of non-steroidal anti-inflammatory drugs (NSAIDs) and the prevention of colorectal cancer (CRC). The consumption of NSAIDs is not problem free, and the number of deaths due to NSAIDs equals the number of deaths from AIDS or leukemia. Therefore, although chemoprevention of CRC is possible, drugs that have more acceptable side effect profiles than the currently available NSAIDs are required. Since up to 50% of polyps and 85% of colonic tumors in humans overexpress cyclooxygenase (COX-2), COX-2 inhibitors are an ideal drug candidate for CRC prevention or treatment
© 2005 S. Karger AG, Basel
Stewart BW, Kleinhues P (eds): World Cancer Report. Lyon, IARC, 2003, pp 198–202.
Morson B: President’s address. The polyp-cancer sequence in the large bowel. Proc R Soc Med 1974;67:451–457.
- Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990;61:759–767.
- Winawer SJ, Zauber AG, O’Brien MJ: Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. N Engl J Med 1993;328:901–906.
- Montoya RG, Wargovich MJ: Chemoprevention of gastrointestinal cancer. Cancer Metastasis Rev 1997;16:405–419.
- Thun MJ: NSAIDs use and decreased risk of gastrointestinal cancers. Gastroenterol Clin North Am 1996;25:333–347.
- Greenberg ER, Baron JA, Freeman DHJ, et al: Reduced risk of large-bowel adenomas among aspirin users: the Polyp Prevention Study Group. J Natl Cancer Inst 1993;85:912–916.
- Thun MJ, Namboodiri MM, Heath CW: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593–1596.
- Shiff SJ, Rigas B: Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology 1997;113:1992–1998.
- Sheng H, Shao J, Kirkland SC: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254–2259.
- Reddy BS, Rao CV, Seibert K: Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996;56:4566–4571.
- Waddell WR, Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 1983;24:83–87.
- Arber N, Strul H: Non-steroidal anti-inflammatory drugs and selective apoptotic anti-neoplastic drugs in the prevention of colorectal cancer: the role of super aspirins. Isr Med Assoc J 2000;2:695–702.
- Oshima M, Oshima H, Kitagawa K: Loss of APC heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated APC gene. Proc Natl Acad Sci USA 1995;92:4482–4486.
- Kune GA, Kune S, Watson LF: Colorectal cancer risk, chronic illnesses, operations, and medications: case control result from the Melbourne Colorectal Cancer Study. Cancer Res 1988;48:4399–4404.
- Smalley W, Ray WA, Daugherty J, Griffin MR: Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer. Arch Int Med 1999;159:161–166.
- Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE: Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609–614.
- Sandler RS, Calanko JC, Murry SC, Helam JF, Woosley JT: Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 1998;114:441–447.
- Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888–1899.
Ahnen DJ: Colon cancer prevention by NSAIDs: what is the mechanism of action? EurJ Surg 1998;582(suppl):111–114.
- Taketo MM: Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998;90:1529–1536.
- Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN: Up-regulation of cyclooxygenase-2 gene expression in human colorectal and adenocarcinomas. Gastroenterology 1994;107:1183–1188.
- Williams CS, Smalley W, DuBois RN: Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 1997;100:1325–1329.
Kelloff G: Chemoprevention of colorectal cancer; in Young G, Rozen P, Levin B (eds): Prevention and Early Detection of CRC. Philadelphia, Saunders, 1996, pp 116–139.
- Reddy BS, Tokumo K, Kulkarni N, Aligia C, Kelloff G: Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 1992;13:1019–1023.
- Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM: Suppression of intestinal polyposis in APC knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803–809.
- Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946–1952.
- Hallak A, Alon-Baron L, Shamir R, Moshkowitz M, Bulvik B, Brazowski E, Halpern Z, Arber N: Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 2003;48:1998–2002.
- Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092–1102.
- Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071–1080.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.